Iron deficiency anemia in HIV infection: Immunologic and virologic response

Journal of the National Medical Association

Volumn 94, Issue 2, 2002, Pages 73-77

  Afacan, Yusuf E ^a   Hasan, Muhammad S ^a   Omene, Jackson A ^a,b  

^a AIDS Center Program   (United States)

^b WOODHULL MEDICAL CENTER   (United States)

Author keywords

HIV infection; Iron deficiency anemia

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; FERRITIN; HEMOGLOBIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IRON; VIRUS RNA;

ADULT; ARTICLE; BLOOD; CASE REPORT; FEMALE; GENETICS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; IRON DEFICIENCY ANEMIA; METABOLISM; MIDDLE AGED; VIROLOGY; VIRUS LOAD;

ADULT; ANEMIA, IRON-DEFICIENCY; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; FEMALE; FERRITINS; HEMOGLOBINS; HIV INFECTIONS; HIV-1; HUMANS; IRON; MIDDLE AGED; NF-KAPPA B; RNA, VIRAL; VIRAL LOAD;

EID: 0036002335     PISSN: 00279684     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Ponka P. Iron deficiency. In: Rakel RE, Bope ET, eds. Conn's Current Therapy, 53rd ed. Philadelphia: Saunders; 2001: 369-380.
2. Monroe JA, Godwin JH, Godwin TA. HIV/AIDS case histories. Iron deficiency anemia and altered iron metabolism in HIV infection. AIDS Patient Care STDs. 2000;12:667-669.
3. Sappey C, Boelaert JR, Legrand PS, et al. Iron chelation decreases NF-kappa B and HIV type I activation due to oxidative stress. AIDS Res Hum Retroviruses. 1995;11:1049-1061.
4. Herzenberg LA, De Rosa SC, Dubs JG, et al. Glutathione deficiency is associated with impaired survival in HIV disease. Proc Natl Acad Sci USA. 1997;94:1967-1972.
5. De Monye C, Karcher DS, Baelaert JR, et al. Bone marrow macrophage iron grade and survival of HIV-seropositive patients. AIDS. 1999;13:375-380.
6. Gennero L, Savarino A, Martini C, et al. Correlation between markers of iron metabolism in HIV-seropositive individuals and in HIV-infected cells. Ligand Assay. 1997;2:182-190.
7. Delange JR, Langlois MR, Boelaert JR, et al. Haptogloglobin polymorphism, iron metabolism and HIV infection. AIDS. 1998;12:1027-1032.
8. Castigliola DG, De Monterlembert M, Lefrere JJ, et al. Dose of deferrioxamine and evolution of HIV infection in thalassaemic patients. Br J Haematol. 1994;87:849-852.
9. Mencacci A, Cencei E, Boelaert JR, et al. Iron overload alter T helper cell responses to candida albicans in mice. J Infect Dis. 1997;175:1467-1476.
10. Weinberg GA. Iron chelators as therapeutic agents against Pneumocystis carinii. Antimicrob Agents Chemother. 1994;38: 997-1003.
11. Dhople AM, Ibanez MA, Poirier TC. Role of iron in the pathogenesis of Mycobacterium avium infection in mice. Microbios. 1996;87:77-87.
12. Beisel WR. Single nutrients and immunity. Am J Clin Nutr. 1982;35:417-468.
13. Murray MJ, Murray HB, Murray MB, et al. The adverse effect of iron repletion on the course of certain infections. BMJ. 1978;2:1113-1115.
14. Georgiou NA, Vander Bruggen T, Oudshoorn M. et al. Inhibition of human immunodeficient virus type I replication in human mononuclear blood cells by iron chelators deferoxamine, deferiprone, and bleomycin. J Infect Dis. 2000;181:484-490.
15. Lederman HM, Cohen A, Lee JWW, et al. Deferoxamine: a reversible S-phase inhibitor of human lymphocyte proliferation. Blood. 1984;64:748-753.
16. Igarashi T, Brown CR, Endo Y, et al. Macrophage are the principal reservoir and sustain high virus loads in rhesus macques after depletion of CD4+ T cells by highly pathogenic simian immunodeficiency virus/HIV type I chimera (SHIV): implications for HIV-1 infections of humans. Proc Natl Acad Sci USA. 2001;98:658-663.
17. Pechet L. Anemias and other red cell disorders. In: Noble J, Greene HL, Modest GA, Levinson W, Young MJ, eds. Primary Care Medicine. St. Louis, MO: Mosby; 1996:722-734.